The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA

HeartFlow, Inc.258 enrolled

Overview

This study will evaluate the level of agreement between noninvasive CCTA (coronary computed tomography angiography)-based quantification and characterization of coronary atherosclerosis and invasive IVUS (intravascular ultrasound).

This is a prospective, multi-center study. All patients who have a stenosis in at least one major epicardial vessel confirmed by CCTA, who have undergone FFRCT (Fractional flow reserve-computed tomography) analysis, and who are scheduled to undergo clinically indicated IVUS-guided invasive evaluation and/or treatment will be eligible for enrollment. Enrolling sites will have FFRCT analysis incorporated when indicated into their standard evaluation of CCTA scans. Data collected will include CCTA and FFRCT, full angiographic, and IVUS images, and if obtained, any other imaging or physiologic data including OCT (Optical coherence tomography), FFR (fractional flow reserve), any NHPR (non-hyperemic pressure ratios) (e.g., dPR (diastolic pressure ratio), RFR (resting full-cycle ratio), iFR (instantaneous wave-free ratio), etc.), and pre- and post-stent implantation invasive data. All non-invasive and invasive data collected will be obtained as clinical practice consistent with standard clinical care.

Study Type

OBSERVATIONAL

Enrollment

258

Conditions

Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))

Interventions

Total Plaque VolumeOTHER

Compare total plaque volume with IVUS obtained during ICA (invasive coronary angiography)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria (all must be present): 1. Age ≥18 years 2. Clinically stable patient with known CAD 3. CCTA showing stenosis in at least one major epicardial vessel of stentable/graftable diameter, in whom clinically indicated IVUS is planned within 45 days of the CCTA and FFRct available 4. FFRct successfully processed 5. Willing to comply with all aspects of the protocol 6. Agrees to be included in the study and able to provide written informed consent. Exclusion criteria (all must be absent): 1. 1\. CCTA showing no stenosis 2. Uninterpretable CCTA by HeartFlow assessment, in which image quality prevents FFRCT from being processed. 3. Acute chest pain 4. CABG (coronary artery bypass graft) prior to CCTA acquisition 5. Prior history of PCI for 3 or more vessels 6. MI (myocardial infarction) less than 30 days prior to CCTA or between CCTA and ICA. 7. Suspicion of acute coronary syndrome (acute myocardial infarction or unstable angina) 8. Known complex congenital heart disease 9. Tachycardia or significant arrhythmia 10. Subject requires an emergent procedure 11. Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \<90 mmHg, and severe congestive heart failure (NYHA \[New York Heart Association\] III or IV) or acute pulmonary edema 12. Any active, serious, life-threatening disease with a life expectancy of less than 2 months 13. Currently enrolled in another study utilizing FFRCT or in an investigational trial that involves a non-approved cardiac drug or device 14. Persons under the protection of justice, guardianship, or curatorship

Locations (1)

HeartFlow Investigative Site

Lincoln, Nebraska, United States

Outcomes

Primary Outcomes

Comparison of Total Plaque Volume

Level of agreement between total plaque volume measured by AI-QCPA (Artificial intelligence quantitative coronary plaque analysis) and IVUS (intravascular ultrasound).

Time frame: 13 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.